SCHEMBL5010378

SCHEMBL5010378

CC(OC(=O)OC1CCCCC1)OC(=O)c1ccc(C(N)=O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP10 Q53GL7 4/20 0.44
▸ STS P08842 4/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ LMNA P02545 2/20 0.42
▸ HTT P42858 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ SCN1A P35498 1/20 0.42
▸ SCN2A Q99250 1/20 0.42
▸ SCN3A Q9NY46 1/20 0.42
▸ PDE4A P27815 1/20 0.41
▸ PDE4B Q07343 1/20 0.41
▸ PDE4C Q08493 1/20 0.41
▸ PDE4D Q08499 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ PARP15 Q460N3 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25913609 0.88 SCN1A (0.48) STSSMN1; SMN2LMNAHTTCYP1A2
SCHEMBL24848168 0.87 MEN1 (0.46) STSSMN1; SMN2LMNAHTTCYP1A2
SCHEMBL25920617 0.86 LMNA (0.56) STSSMN1; SMN2LMNAHTTCYP1A2
SCHEMBL26804979 0.85 RAB9A (0.46) STSSMN1; SMN2LMNAHTTCYP1A2
SCHEMBL5010823 0.85 SMN1; SMN2 (0.49) STSSMN1; SMN2LMNAHTTCYP1A2
SCHEMBL7371640 0.78 EPHX1 (0.39) STSSMN1; SMN2LMNAHTTCYP19A1
SCHEMBL6865989 0.77 ACHE (0.41) LMNACYP1A2CYP2D6NPC1RAB9A
SCHEMBL1378229 0.76 HPGD (0.38) SMN1; SMN2LMNAHTTCYP1A2CYP2D6
SCHEMBL1378233 0.76 ALDH1A1 (0.45) SMN1; SMN2LMNAHTTNPC1RAB9A
SCHEMBL5986431 0.74 EPHX1 (0.40) SMN1; SMN2HTTCYP19A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 — — EP claimed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 — — US claimed
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 — — EP disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents PYGL, GYS2, AGL PARP10 1586/4885STS 255/4885SMN1; SMN2 4705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback